ImaginAb claimed that its recombinant antibody fragments enable development of tailored, specific imaging agents for drug research.
Imanet claimed that its network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET research tracers.
ImaginAb CEO Christian Behrenbruch said that ImaginAb is pleased to have formalised this agreement with Imanet.
"Imanet’s network of pre-clinical and clinical imaging sites and leveraging GE’s expertise in radiochemistry will be invaluable for both our internal product pipeline as well as for ImaginAb’s pharmaceutical partnerships," Behrenbruch said.
"We also intend to work with Imanet to validate our library of pre-clinical imaging probes for microPET and microSPECT imaging."
Imanet Imaging Solutions manager Eric Agdeppa said that ImaginAb has a pipeline of new products that they are pleased to help develop. They also see synergy between Imanet’s capabilities and ImaginAb’s pharmaceutical industry clientele.